The lower risk MDS patient at risk of rapid progression

Leukemia Research

Volumn 34, Issue 12, 2010, Pages 1551-1555

  Mittelman, Moshe ^a   Oster, Howard S ^a   Hoffman, Michael ^a   Neumann, Drorit ^a  

^a TEL AVIV UNIVERSITY   (Israel)

Author keywords

Myelodysplastic syndrome (MDS)

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; ANTIANEMIC AGENT; AZACITIDINE; CASPASE 3; CD11B ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; CYCLIN DEPENDENT KINASE INHIBITOR 2B; CYTARABINE; FERRITIN; GRANULOCYTE COLONY STIMULATING FACTOR; HLA DR ANTIGEN; IMMUNOSUPPRESSIVE AGENT; LACTATE DEHYDROGENASE; LENALIDOMIDE; LYMPHOID ENHANCER FACTOR 1; MICROSOMAL AMINOPEPTIDASE; PROTEIN BCL 2; RECOMBINANT ERYTHROPOIETIN; SURVIVIN; TELOMERASE; THALIDOMIDE;

AGING; APOPTOSIS; CHELATION THERAPY; CHROMOSOMAL INSTABILITY; CHROMOSOME ABERRATION; CLINICAL TRIAL; DISEASE CLASSIFICATION; DISEASE COURSE; DOWN REGULATION; DYSPLASIA; ENZYME ACTIVITY; ERYTHROCYTE TRANSFUSION; GENE EXPRESSION PROFILING; GENE MUTATION; GRANULOCYTE; HIGH RISK PATIENT; HUMAN; IMMUNOPHENOTYPING; IRON OVERLOAD; LOW DRUG DOSE; MYELODYSPLASTIC SYNDROME; MYELOFIBROSIS; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEIN METHYLATION; REVIEW; RISK ASSESSMENT; SCORING SYSTEM; STEM CELL TRANSPLANTATION; TELOMERE;

AGE FACTORS; ALPHA CATENIN; ANTIGENS, DIFFERENTIATION; ANTINEOPLASTIC AGENTS; CASPASE 3; CHROMOSOME ABERRATIONS; CYCLIN-DEPENDENT KINASE INHIBITOR P15; CYTOKINES; DNA METHYLATION; ERYTHROCYTE TRANSFUSION; FEMALE; FERRITINS; FIBROSIS; GENE EXPRESSION REGULATION; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; LEUKOCYTE COUNT; LIPOPROTEINS, LDL; LYMPHOID ENHANCER-BINDING FACTOR 1; MALE; MICROTUBULE-ASSOCIATED PROTEINS; MUTATION; MYELODYSPLASTIC SYNDROMES; PLATELET COUNT; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; RECEPTOR PROTEIN-TYROSINE KINASES; RISK FACTORS; SEX FACTORS; THALIDOMIDE;

EID: 78149358704     PISSN: 01452126     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.leukres.2010.05.023     Document Type: Review

References (79)

1. De Angelo D.J., Stone R.M. Myelodysplastic syndromes: biology and treatment. Hematology - basic principles and practice 2005, 1195-1208. Elsevier, Philadelphia. 4th ed. R. Hoffman (Ed.).
2. Mittelman M. The myelodysplastic syndromes - 1990. Isr J Med Sci 1990, 26:468-478.
3. Bowen D., Culligan D., Jowitt S., et al. Guidelines for the diagnosis and therapy of adult myelodysplastic syndromes. Br J Haematol 2003, 120:187-2000.
4. List AF, Pedersen-Bjergaard J, Garcia-Manero G. Myelodysplastic synsdromes. Hematology 2007 - Am Soc Hem Education Program Book, p. 392-411.
5. Nimer SD, Hellstrom-Lindberg E, Cazzola M, Kroger N. Myelodysplastic syndromes. Hematology 2008 - Am Soc Hem Education Program Book, p. 43-67.
6. Steensma DP, Sekeres MA, Leitch HA, Vickars LM. Myelodysplastic syndromes. Hematology 2009 - Am Soc Hem Education Program Book, p. 645-674.
7. Tefferi A., Vardiman J.W. Myelodysplastic syndromes. N Engl J Med 2009, 361:1872-1885.
8. Greenberg P., Cox C., LeBeau M.M., et al. International scoring system for evaluating prognosis in myelodysplastic syndromes. Blood 1997, 89:2079-2098.
9. Bennett J.M., Catovski D., Daniel M.T., et al. Proposals for the classification of the myelodysplastic syndromes. Br J Haematol 1982, 51:189-199.
10. Mittelman M., Floru S., Djaldetti M. Subcutaneous erythropoietin for treatment of refractory anemia in hematologic disorders. Blood 1992, 80:841-842.
11. Hellstrom-Lindberg E., Gulbrandsen N., Lindberg G., et al. A validated decision model for treating the anaemia of myelodysplastic syndromes with erythropoietin+granulocyte colony-stimulating factor: significant effects of on quality of life. Br J Haematol 2003, 120:1037-1046.
12. Hellstrom-Lindberg E., Negrin R., Stein R., et al. Erythroid response to treatment with G-CSF plus erythropoietin for the anemia of patients with myelodysplastic syndrome: proposal for a preditive model. Br J Haematol 1997, 99:344-351.
13. Jadersten M., Malcovati L., Dybedal I., et al. Erythropoietin and granulocyte-colony stimulating factor treatment associated with improved survival in myelodysplastic syndrome. J Clin Oncol 2008, 26:3607-3613.
14. Kantarjian H., Feneaux P., Sekeres M.A., et al. Safety and efficacy of romiplostim in patients with low-risk myelodysplastic syndrome and thrombocytopenia. J Clin Oncol 2010, 28:437-444.
15. Raza A., Meyer P., Dutt D., et al. Thalidomide produces transfusion independence in log-standing refractory anemias of patients with myelodysplastic syndromes. Blood 2001, 98:958-965.
16. List A., Dewald G., Bennett J., et al. Lenalidomide in the myelodysplastic syndrome with chromosome 5q deletion. N Engl J Med 2006, 355:1456-1465.
17. Raza A., Reeves J.A., Feldman E.J., et al. Phase 2 study of lenalidomide in transfusion-dependent, low-risk and intermediate-1-risk myelodysplastic syndromes with karyotypes other than deletion 5q. Blood 2008, 111:86-93.
18. Fenaux P., Giagounidis A., Selleslag D., et al. RBC transfusion independence and safety profile of lenalidomide 5 or 10mg in pts with low- or Int-1-risk MDS with del 5q-: results from a randomized phase III trial (MDS-004). Blood 2009, 114. [Abs # 944].
19. Molldrem J., Leifer E., Bahceci E., et al. Anti thymocyte globulin to treatment of the bone marrow failure associated with myelodysplastic syndromes. Ann Intern Med 2002, 137:156-163.
20. Bennett J.M. Consensus statement on iron overload in myelodysplastic syndromes. Am J Hematol 2008, 83:859-861.
21. Mittelman M., Lugassy G., Merkel D., et al. Iron chelation therapy in patients with myelodysplastic syndromes - consensus conference guidelines (For the MDS Israel Group and The Israel Society of Hematology). Isr Med Assoc J 2008, 10:374-376.
22. Gore S.D., Baylin S., Sugar E., et al. Combined DNA methyl transferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 2006, 66:6361-6369.
23. Silverman L.R., McKenzie D.R., Peterson B.L., et al. Further analysis of trials with azacitidine in patients with myelodysplastic syndrome: studies 8241, 8921, and 9221 by the Cancer and Leukemia Group B. J Clin Oncol 2006, 24:3895-3903.
24. Fenaux P., Mufti G.J., Hellstrom-Lindberg E., et al. Efficacy of azacitidine compared with that of conventional care regimens in the treatment of higher-risk myelodysplastic syndromes: a randomized, open-label, phase III study. Lancet Oncol 2009, 10:223-232.
25. de Witte T., Suciu S., Verhoef G., et al. Intensive chemotherapy followed by allogeneic or autologous stem cell transplantation for patients with myelodysplastic syndromes (MDSs) and acute myeloid leukemia following MDS. Blood 2001, 98:2326-2331.
26. Deeg H.J., Storer B., Slattery J.T., et al. Conditioning with targeted busulfan and cyclophosphamide for hemopoietic stem cell transplantation from related and unrelated donors in patients with myelodysplastic syndrome. Blood 2002, 100:1201-1207.
27. Germing U., Hildebrandt B., Pfeilstocker M., et al. Refinement of the International Prognostic Scoring system (IPSS) by including LDH as an additional prognostic variable to improve risk assessment in patients with primary myelodysplastic syndromes (MDS). Leukemia 2005, 19:2223-2231.
28. Kao J.M., McMillan A., Greenberg P.L. International MDS risk analysis workshop (IMRAW)/IPSS reanalyzed: impact of cytopenias on clinical outcomes in myelodysplastic syndromes. Am J Hematol 2008, 83:765-770.
29. Kantajian H., O'Brien S., Ravandi F., et al. Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System. Cancer 2008, 113:1351-1361.
30. Wang X.O., Ryder J., Gross S.A., et al. Prospective analysis of clinical and cytogenetic features of 435 cases of MDS diagnosed using the WHO (2001) classification: a prognostic scoring system for predicting survival in RCMD. Int J Hematol 2009, 90:361-369.
31. Kuendgen A., Strupp C., Aivado M., et al. Myelodysplastic syndromes in patients younger than age 50. J Clin Oncol 2006, 24:5358-5365.
32. Nosslinger T., Tuchler H., Germing U., et al. Prognostic impact of age and gender in 897 untreated patients with primary myelodysplastic syndromes. Ann Oncol 2010, 21:120-125.
33. Sperr W.R., Wimazal F., Kundi M., et al. Comorbidity as prognostic variable in MDS: comparative evaluation of the HCT-Ci and CCI in a core dataset of 149 patients of the Austrian MDS Study Group. Ann Oncol 2010, 21:114-119.
34. Cazzola M., Malcovati L. Myelodysplastic syndromes - coping with ineffective hematopoiesis. N Engl J Med 2005, 352:536-538.
35. Malcovati L., Della Porta M., Pascutto C., et al. Prognostic factors and life expectancy in myelodysplastic syndromes classified according to WHO criteria: a basis for clinical decision-making. J Clin Oncol 2005, 23:7594-7603.
36. Malcovati L., Germing U., Kuendgen A., et al. Time-dependent prognostic scoring system for predicting survival and leukemic evolution in myelodysplastic syndromes. J Clin Oncol 2007, 25:3503-3510.
37. Cermak J., Kacirkova P., Mikulenkova D., Michalova K. Impact of transfusion dependency on survival in patients with early myelodysplastic syndrome without excess blasts. Leuk Res 2009, 33:1469-1474.
38. Tricot G., De Wolf-Peeters C., Vietinck R., Verwilghen R.L. Bone marrow histology in myelodysplastic syndromes. II. Prognostic value of abnormal localization of immature precursors in MDS. Br J Haematol 1984, 58:217-225.
39. Della Porta M.G., Malcovati L., Boveri E., et al. Clinical relevance of bone marrow fibrosis and CD34-positive cell clusters in primary myelodysplastic syndromes. J Clin Oncol 2009, 27:754-762.
40. Orazi A. Histopathology in the diagnosis and classification of acute myeloid leukemia, myelodysplastic syndromes, and myelodysplastic/myeloproliferative diseases. Pathobiology 2007, 74:97-114.
41. Cermak J., Belickova M., Krejcova H., et al. The presence of clonal cell subpopulations in peripheral blood and bone marrow of patients with refractory cytopenia with multilineage dysplasia but not in patients with refractory anemia may reflect a multistep pathogenesis of myelodysplasia. Leuk Res 2005, 29:371-379.
42. Yue G., Hao S., Fadare O., et al. Hypocellularity in myelodysplastic syndrome is an independent factor which predicts a favorable outcome. Leuk Res 2008, 32:553-558.
43. Mittelman M., Karcher D.S., Kammerman L.A., Lessin L.S. High Ia (HLA-DR) and low CD11b (Mo1) expression may predict early conversion to leukemia in myelodysplastic syndromes. Am J Hematol 1993, 43:165-171.
44. Lorand-Metz I., Califani S.M., Ribeiro E., et al. The prognostic value of maturation-associated phenotypic abnormalities in myelodysplastic syndromes. Leuk Res 2008, 32:205-207.
45. van de Loosdrecht A.A., Westers T.M., Westra A.H., et al. Identification of distinct prognostic subgroups in low- and intermediate-1-risk myelodysplastic syndromes by flowcytometry. Blood 2008, 111:1067-1077.
46. Kantarjian H., O'Brien S., Ravandi F., et al. The heterogenous prognosis of patients with myelodysplastic syndrome and chromosome 5 abnormalities: how does it relate to the original lenalidomide experience in MDS?. Cancer 2009, 115:5202-5209.
47. Helig C.E., Loffler H., Mahlknecht U., et al. Chromosomal instability correlates with poor outcome in patients with myelodysplastic syndromes irrespectively of the cytogenetic risk group. J Cell Mol Med 2009, (September). [on line].
48. Ohyashiki J.H., Ohyashiki K., Fujimura T., et al. Telomere shortening associated with disease evolution patterns in myelodysplastic syndromes. Cancer Res 1994, 54:3557-3560.
49. Ohyashiki K., Iwama H., Yahata N., et al. Telomere dynamics in myelodysplastic syndromes and acute leukemic transformation. Leuk Lymphoma 2001, 42:291-299.
50. Sieglova Z., Zilovcova S., Cermak J., et al. Dynamics of telomere erosion and its association with genome instability in myelodysplastic syndromes (MDS) and acute myelogenous leukemia arising from MDS: a marker of disease prognosis?. Leuk Res 2004, 28:1013-1021.
51. Fern L., Pallis M., Ian Carter G., et al. Clonal haemopoiesis may occur after conventional chemotherapy and is associated with accelerated telomere shortening and defects in the NQO1 pathway; possible mechanisms leading to an increased risk of t-AML/MDS. Br J Haematol 2004, 126:63-71.
52. Li B., Yang J., Andrews C., et al. Telomerase activity in preleukemia and acute myelogenous leukemia. Leuk Lymphoma 2000, 36:579-587.
53. Gurkan E., Tanriverdi K., Baslamisli F. Telomerase activity in myelodysplastic syndromes. Leuk Res 2005, 29:1131-1139.
54. Fu C., Chen Z. Telomerase activity in myelodysplastic syndrome. Chin Med J 2002, 115:1475-1478.
55. Raza A., Gezer S., Mundle S., et al. Apoptosis in bone marrow biopsy sample involving stromal and hematopoietic cells in 50 patients with myelodysplastic syndromes. Blood 1995, 86:268.
56. Davis R.E., Greenberg P.L. Bcl-2 expression by myeloid precursors in myelodysplastic syndromes: relation to disease progression. Leuk Res 1998, 22:767-777.
57. Ohshima K., Karube K., Shimazaki K., et al. Imbalance between apoptosis and telomerase activity in myelodysplastic syndromes: possible role in ineffective hemopoiesis. Leuk Lymphoma 2003, 44:1339-1346.
58. Invernizi R., Travaglino E., Klersy C., et al. Survivin expression in acute leukemias and myelodysplastic syndromes. Leuk Lymphoma 2004, 45:2229-2237.
59. Yamamoto K., Abe S., Nakagawa Y., et al. Expression of IAP family proteinsin myelodysplastic syndromes transforming to overt leukemia. Leuk Res 2004, 28:1203-1211.
60. Gianelli U., Fracchiolla N.S., Cortelezzi A., et al. Survivin expression in " low-risk" and " high-risk" myelodysplastic syndromes. Ann Hematol 2007, 86:185-189.
61. Wang Y.Y., Cen J.N., He J., et al. Accelerated cellular senescence in myelodysplastic syndrome. Exp Hematol 2009, 37:1310-1317.
62. Quesnel B., Guillerm G., Vereeccque R., et al. Methylation of p15 (INK4b) gene in myelodysplastic syndromes is frequent and acquired during disease progression. Blood 1998, 91:2985-2990.
63. Kim M., Oh B., Kim S.Y., et al. p15INK4b methylation correlates with thrombocytopenia, blast percentage, and survival in myelodysplastic syndromes in a dose dependent manner: quantitation using pyrosequencing study. Leuk Res 2009, (September). [on line].
64. Ye Y., McDevitt M.A., Guo M., et al. Progressive chromatin repression and promoter methylation of CTNNA1 associated with advanced myeloid malignancies. Cancer Res 2009, 69:8482-8490.
65. Shen L., Kantarjian H., Guo Y., et al. DNA methylation predicts survival and response to therapy in patients with myelodysplastic syndromes. J Clin Oncol 2010, 28:605-613.
66. Kosmider O., Gelsi-Boyer V., Cheok M., et al. TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). Blood 2009, 114:3285-3291.
67. Pellagatti A., Marafioti T., Paterson J.C., et al. Marked down regulation of the granulopoiesis regulator LEF1 is associated with disease progression in the myelodysplastic syndromes. Br J Haematol 2009, 146:86-90.
68. Boultwood J., Perry J., Pellagatti A., et al. Frequent mutations of the polycomb-associated gene ASXL1 in myelodysplastic syndromes and acute myeloid leukemia. Blood 2009, 114(Suppl.). [Am Soc Hem (ASH)].
69. Sridhar K., Ross D.T., Tibshirani R., et al. Relationship of differential gene expression profiles in CD34+ myelodysplastic syndrome marrow cells to disease subtype and progression. Blood 2009, 114:4847-4858.
70. Mittelman M., Zeidman A., Kanter P., Katz O., Oster H., Rund D., et al. Erythropoietin has an anti-myeloma effect - a clinical observation supported by animal studies. Eur J Haematol 2004, 72:155-165.
71. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and anti-tumor immune responses in murine myeloma models. Proc Natl Acad Sci USA 2001, 98:5181-5186.
72. Prutchi-Sagiv S., Golishevsky N., Oster H.S., Katz O., Cohen A., Naparstek E., et al. Erythropoietin treatment in advanced multiple myeloma is associated with improved immunological functions: could it be beneficial in early disease?. Br J Haematol 2006, 135:660-672.
73. Prutchi-Sagiv S., Golishevski N., Katz O., Oster H.S., Naparstek E., Hoffman M., et al. T-cell abnormalities in patients with myelodysplastic syndromes: improved immunological functions in patients treated with recombinant erythropoietin. Blood 2006, 108(756a). [Abs # 2675].
74. Littlewood T.J., Bajetta E., Nortier J.W., et al. Effects of epoetin alfa on hematologic parameters and quality of life in cancer patients receiving nonplatinum chemotherapy: results of a randomized, double-blind, placebo-controlled trial. J Clin Oncol 2001, 19:2865-2874.
75. Wallvik J., Stenke L., Bernell P., et al. Serum erythropoietin (EPO) levels correlate with survival and independently predict response to EPO treatment in patients with myelodysplastic syndromes. Eur J Haematol 2002, 68:180-185.
76. Park S., Grabar S., Kelaidi C., et al. Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. Blood 2008, 111:574-582.
77. Rose C, Brechignac S, Vassilief D, et al. Positive impact of iron chelation therapy (CT) on survival in regularly transfused MDS patients. A prospective analysis by the GFM. Leuk Res in press [Blood 2007;110(Suppl.):80-81 (abstract)].
78. Leitch H.A., Leger C.S., Goodman T.A., et al. Improved survival in patients with myelodysplastic syndrome receiving iron chelation therapy. Clin Leuk 2008, 2:205-211.
79. Alessandrino E.P., Della Porta M.G., Bacigalupo A., et al. WHO classification and WPSS predict post transplantation outcome in patients with myelodysplastic syndrome: a study from the Gruppo Italiano Trapianto di Midollo Osseo (GITMO). Blood 2008, 112:895-902.